M. Loriaux

发表

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

B. Druker, M. Muschen, J. Tyner, 2012, Cancer cell.

RNAi screen for rapid therapeutic target identification in leukemia patients

B. Druker, M. Heinrich, M. Deininger, 2009, Proceedings of the National Academy of Sciences.

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

Stefan Fröhling, Benjamin L Ebert, Todd R Golub, 2007, Cancer cell.

Small Intestinal Submucosa Plug for Closure of Dilated Nephrostomy Tracts: A Pilot Study in Swine

Young Hwan Kim, Young Hwan Kim, F. Keller, 2010, CardioVascular and Interventional Radiology.

Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.

Armand Bankhead, Guang Fan, M. D. Den Boer, 2013, Cancer research.

Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia

M. Heinrich, C. Corless, J. Tyner, 2012, Leukemia.

TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics*

Akhilesh Pandey, Xinyan Wu, John Rush, 2012, Molecular & Cellular Proteomics.

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

M. Loh, S. Armstrong, E. Estey, 2005, Blood.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Angela G. Fleischman, B. Druker, M. Deininger, 2011, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

R. Ulrich, J. Byrd, A. Johnson, 2011, Blood.

SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia

M. Loriaux, S. Spurgeon, A. Danilov, 2017, Haematologica.

A BCR-ABL Mutant Lacking Direct Binding Sites for the GRB2, CBL and CRKL Adapter Proteins Fails to Induce Leukemia in Mice

B. Druker, A. Corbin, M. Deininger, 2009, PloS one.

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I

Emily A. Stevens, P. Greenberg, J. Tyner, 2015, Clinical Cancer Research.

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

Angela G. Fleischman, B. Druker, A. Agarwal, 2013, Blood.

Modulatory function of CREB.CREM alpha heterodimers depends upon CREM alpha phosphorylation.

R. Brennan, R. Goodman, M. Loriaux, 1994, The Journal of biological chemistry.

Absence of Skp2 Expression Attenuates Bcr-abl-induced

K. Nakayama, B. Druker, A. Corbin, 2008 .

Aurora A kinase as a target for therapy in TCF3-HLF rearranged acute lymphoblastic leukemia

M. Loh, C. Mullighan, B. Druker, 2021, Haematologica.

A case study of personalized therapy for osteosarcoma

C. Keller, J. Tyner, M. Loriaux, 2013, Pediatric blood & cancer.

leukemia or chronic lymphocytic leukemia leukemia and acute myeloid leukemia, but not in acute lymphoblastic The JAK2V617F activating mutation occurs in chronic myelomonocytic

Avis J. Thomas, M. Loh, S. Armstrong, 2013 .

Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.

R. Braziel, M. Loriaux, S. Olson, 2011, American journal of clinical pathology.

The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia , but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

M. Loh, S. Armstrong, E. Estey, 2005 .

acute lymphoblastic The JAK 2 V 617 F activating mutation occurs in chronic myelomonocytic

M. Loh, S. Armstrong, E. Estey, 2005 .

MET receptor sequence variants R970C and T992I lack transforming capacity.

B. Druker, M. Mori, M. Heinrich, 2010, Cancer research.

The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia

B. Druker, J. Tyner, M. Loriaux, 2013, The Journal of Pharmacology and Experimental Therapeutics.

mutations in myeloid leukemia patients High-throughput sequencing screen reveals novel, transforming RAS

B. Druker, M. Heinrich, D. Gilliland, 2013 .

Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia.

B. Druker, A. Corbin, M. Deininger, 2006, Experimental hematology.

Survey of Activated FLT3 Signaling in Leukemia Please share how this access benefits you. Your story matters

S. Gygi, J. Kornhauser, J. Villén, 2011 .

JAK2 V617F Mutation Induces a Myeloproliferative Disorder in Mice.

B. Druker, M. Deininger, M. Loriaux, 2005 .

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

T. Golub, S. Fröhling, B. Ebert, 2007, Cancer cell.

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.

R. Collins, A. Cohen, Guanming Wu, 2022, Cancer cell.

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

B. Druker, J. Tyner, B. Chang, 2012, Pediatric blood & cancer.

Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine

D. Bottomly, S. McWeeney, B. Druker, 2013, Genome Medicine.

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma

B. Druker, J. Tyner, M. Loriaux, 2015, Oncotarget.

c-CBL is not required for leukemia induction by Bcr-Abl in mice

B. Druker, C. Corless, M. Deininger, 2003, Oncogene.

The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A.

R. Goodman, M. Loriaux, K. Walton, 1991, The Journal of biological chemistry.

Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia

S. McWeeney, B. Druker, C. Tognon, 2016 .

Gene expression profiling of CML CD34+ cells prior to imatinib therapy reveals differences between patients with and without subsequent complete cytogenetic response

Y. Turpaz, C. Harrington, S. McWeeney, 2005 .

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.

Angela G. Fleischman, B. Druker, R. Woltjer, 2012, Blood.

YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway

C. Mullighan, B. Druker, J. Tyner, 2015, Journal of Hematology & Oncology.

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma

M. Loriaux, G. Thomas, R. Amaravadi, 2017, Haematologica.

CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

E. Traer, J. Tyner, M. Loriaux, 2017, Leukemia research.

Functional Genomic Landscape of Acute Myeloid Leukemia

Beth Wilmot, Erik Segerdell, Shannon K. McWeeney, 2018, Nature.

Utility of Multiplex Mutation Analysis in the Diagnosis of Chronic Myelomonocytic Leukemia

R. Braziel, D. Ang, C. Corless, 2013 .

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

T. Clackson, B. Druker, A. Corbin, 2009, Cancer cell.

The square stent-based large vessel occluder: an experimental pilot study.

F. Keller, C. Corless, J. Rösch, 2000, Journal of vascular and interventional radiology : JVIR.

Stent-grafts for de novo TIPS: technique and early results.

J. Rabkin, F. Keller, J. Rösch, 1999, Journal of vascular and interventional radiology : JVIR.

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

T. Clackson, B. Druker, J. Tyner, 2011, Molecular Cancer Therapeutics.

Preclinical Development Potent Activity of Ponatinib ( AP 24534 ) in Models of FLT 3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

T. Clackson, B. Druker, J. Tyner, 2011 .

CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes

S. McWeeney, B. Druker, A. Agarwal, 2015 .

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

B. Druker, M. Loriaux, R. Burke, 2014, Oncotarget.

Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma

Guo Ci Teo, Meghan C. Burke, Jeffrey R. Whiteaker, 2020, Cell.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

R. Levine, B. Druker, M. Heinrich, 2009, Blood.

Therapeutically Targetable ALK Mutations in Leukemia.

D. Bottomly, S. McWeeney, B. Druker, 2015, Cancer research.

with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34

Y. Turpaz, C. Harrington, S. McWeeney, 2011 .

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.

B. Druker, M. Deininger, J. Tyner, 2010, Blood.

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Beth Wilmot, Shannon K McWeeney, Jennifer L. Snead, 2010, Blood.

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia

D. Bottomly, S. McWeeney, J. Tyner, 2018, Science Signaling.

Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression.

K. Loeb, J. Radich, C. Eaves, 2015, Blood.

Functional genomic landscape of acute myeloid leukaemia

R. Collins, D. Bottomly, S. McWeeney, 2018, Nature.

acute myeloid leukemia RNAi screening of the tyrosine kinome identifies therapeutic targets in

B. Druker, M. Heinrich, A. Corbin, 2013 .

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

B. Druker, M. Heinrich, A. Corbin, 2008, Blood.

Survey of Activated FLT3 Signaling in Leukemia

S. Gygi, J. Kornhauser, S. Beausoleil, 2011, PloS one.

Survey of Activated FLT 3 Signaling in Leukemia

S. Gygi, J. Kornhauser, S. Beausoleil, 2011 .

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

B. Druker, J. Cortes, A. Corbin, 2011, The Journal of clinical investigation.

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

S. Fröhling, R. Levine, R. Berger, 2007, Blood.

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Angela G. Fleischman, R. Collins, D. Bottomly, 2013, The New England journal of medicine.

Characterization of murine JAK2V617F-positive myeloproliferative disease.

B. Druker, A. Corbin, M. Deininger, 2006, Cancer research.

Absence of SKP 2 expression attenuates BCR-ABL-induced

K. Nakayama, B. Druker, A. Corbin, 2008 .

Activating alleles of JAK3 in acute megakaryoblastic leukemia.

Sandra A. Moore, T. Boggon, J. Nardone, 2006, Cancer cell.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia

B. Druker, E. Traer, J. Tyner, 2016, Science Translational Medicine.

An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.

R. Pal, C. Keller, J. Michalek, 2012, Biochemical and biophysical research communications.

Crosstalk between ROR 1 and the pre-B-Cell Receptor Promotes Survival of t ( 1 ; 19 ) Acute Lymphoblastic Leukemia

B. Druker, M. Muschen, J. Tyner, 2012 .

Therapeutically Targetable ALK Mutations in

D. Bottomly, S. McWeeney, B. Druker, 2015 .

Clonal Cytogenetic Abnormalities in Philadelphia Chromosome Negative Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib

M. Deininger, M. Loriaux, 2004, Leukemia & lymphoma.

Acute graft‐versus‐host disease of the heart

M. Loriaux, Meei-Li W Huang, C. Thiede, 2006, Pediatric blood & cancer.

Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.

B. Druker, J. Tyner, M. Loriaux, 2013, Translational oncology.

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate

R. Braziel, B. Druker, M. Loriaux, 2003, Leukemia.

Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia

S. McWeeney, B. Druker, M. Mori, 2020, Proceedings of the National Academy of Sciences.

CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

Ted Laderas, Shannon K McWeeney, Mara Rosenberg, 2019, Blood.

Polyurethane-coated dacron-covered stent-grafts for TIPS: results in swine

M. Loriaux, A. Krajina, D. Pavčnik, 1998, CardioVascular and Interventional Radiology.

Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes

J. Chevillet, C. Roberts, B. Chang, 2015, Leukemia.

Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance

A. Agarwal, E. Traer, J. Tyner, 2016, British journal of haematology.

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

James M. Roberts, Angela G. Fleischman, S. McWeeney, 2014, Blood.

oncoprotein BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic

James M. Roberts, S. McWeeney, J. Cortes, 2014 .

CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway

B. Druker, J. Tyner, M. Loriaux, 2013, Leukemia.

Thrombus Formation After Percutaneous Catheterization and Manual Compression of the Femoral Artery in Heparinized Sheep

Young Hwan Kim, A. Burke, F. Keller, 2010, CardioVascular and Interventional Radiology.

Engineered leucine zippers show that hemiphosphorylated CREB complexes are transcriptionally active.

R. Brennan, R. Goodman, M. Loriaux, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples

S. McWeeney, B. Druker, A. Agarwal, 2018, Oncotarget.

Fallopian tube occlusion with use of a small intestine submucosa device: evaluation in a rabbit model.

J. Rösch, M. Loriaux, C. Binkert, 2004, Journal of vascular and interventional radiology : JVIR.

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

J. Tyner, M. Loriaux, L. Mayer, 2010 .

HitWalker: variant prioritization for personalized functional cancer genomics

Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, 2013, Bioinform..

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

M. Deininger, J. Tyner, M. Loriaux, 2011 .

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation

H. Erickson, J. Tyner, M. Loriaux, 2009, Leukemia.

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets

B. Druker, M. Heinrich, A. Corbin, 2008 .

Ph-positive and -negative myeloproliferative syndromes may co-exist

M. Loriaux, M. Mauro, M. Deininger, 2004, Leukemia.

Mast cell sarcoma with concurrent mast cell leukaemia

Philipp W. Raess, R. Braziel, M. Loriaux, 2020, British journal of haematology.

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia

H. Erickson, J. Tyner, M. Loriaux, 2009, Leukemia.

Creation of fibrinogen-enhanced experimental blood clots to evaluate mechanical thrombectomy devices for treatment of acute stroke: an in vitro study.

F. Keller, M. Loriaux, G. Nesbit, 2012, Journal of vascular and interventional radiology : JVIR.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI: 10.1172/JCI35721)

B. Druker, J. Cortes, A. Corbin, 2011 .

TNF-alpha Plays a Crucial Role in the JAK2-V617F Induced Myeloproliferative Disorder.

B. Druker, M. Deininger, M. Loriaux, 2007 .

Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia.

B. Druker, M. Muschen, J. Tyner, 2012, Cancer cell.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

B. Druker, J. Cortes, A. Corbin, 2011, The Journal of clinical investigation.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.

R. Collins, A. Cohen, Guanming Wu, 2022, Cancer cell.

Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.

R. Braziel, M. Heinrich, C. Corless, 2012, Human pathology.

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Angela G. Fleischman, B. Druker, M. Deininger, 2011, Blood.

CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia

Angela G. Fleischman, B. Druker, A. Agarwal, 2013 .

Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.

K. Nakayama, B. Druker, A. Corbin, 2008, Blood.